Key Questions 340B Providers Should Ask When Choosing a TPA

SPONSORED CONTENT

Program integrity is crucial to the management of a covered entity’s 340B operations.  Key components include knowing what is expected of the covered entity and having the right questions to ask your third party administrator about their practices and software.  The purpose of this article is to highlight valuable objectives to have

Read More »

In What Could be the First of Many Challenges, Lilly Appealing U.S. District Court’s 340B Contract Pharmacy Ruling

Lilly yesterday filed notice that it is appealing a federal district judge's decision in its 340B contract pharmacy lawsuit.

Drug manufacturer Eli Lilly late yesterday filed notice that it is appealing a federal district judge’s Oct. 29 ruling partially in Lilly’s favor and partially for the federal government on the legality of Lilly’s denials of 340B ceiling prices when

Read More »

In Pursuit of New 340B Leader, HRSA Expands Its Search Beyond Pharmacists

In a major shift, HRSA has dropped its requirement that the Director of the Office of Pharmacy Affairs (OPA) must have a pharmacy degree and be a licensed pharmacist.

In a major organizational change, the U.S. Health Resources and Services Administration (HRSA) has redefined the job of Director of the Office of Pharmacy Affairs (OPA), the HRSA unit that runs the 340B program.

For the first time in 340B

Read More »

340B Providers Appear to Escape Bullet as Negotiations Continue on Build Back Better Bill’s Drug Pricing Provisions

The Build Back Better bill is still bogged down by infighting among Democrats, and its numerous drug pricing provisions will likely undergo changes prior to any votes.

Although Congress was able to pass a $1.2 trillion bipartisan infrastructure package last week, the nearly $1.8 trillion Build Back Better bill remains bogged down by infighting among Democrats. Its numerous drug pricing provisions will likely undergo changes prior to

Read More »

Attention Turns to Merck and AstraZeneca After Courts’ 340B Contract Pharmacy Rulings

The timing of the government’s forthcoming decision on the legality of Merck’s 340B contract pharmacy policy, and the grounds for its decision, are two big questions hovering over the 340B program.

The smoke is still clearing from three federal district judges’ recent decisions in drug manufacturers Lilly, Sanofi, Novo Nordisk, Novartis, and United Therapeutics’ 340B contract pharmacy lawsuits. In the rulings’ wake, we are keeping close tabs on what happens next

Read More »

Hospitals, Drug Manufacturers, and Lawyers Give their Takes on 340B Contract Pharmacy Rulings

A hospital group, drug manufacturers, and health care lawyers gave 340B Report their views on recent court rulings in five 340B contract pharmacy lawsuits.

A hospital group says two federal district judges got it right, but one got it wrong, on whether drug manufacturers are legally bound to provide 340B drug discounts for drugs dispensed at contract pharmacies.

In a Nov. 6 statement, 340B

Read More »

Two New Studies on Hospital and Health Center Participation in 340B

Rush University Medical Center was included in a JAMA Internal Medicine study of what top hospitals charge commercial insurers for clinician-administered drugs.

A new research letter published in JAMA Internal Medicine found substantial variation among 17 “top-performing” hospitals—14 of them enrolled in 340B—in what they charge commercial insurers for clinician-administered drugs.

Meanwhile, new research published in Journal of Healthcare Quality found that

Read More »

Breaking News

Breaking: Another Federal Judge Issues a Mixed Opinion in 340B Contract Pharmacy Litigation, this Time in Novartis and United Therapeutics’ Cases

U.S. District Judge Dabney Friedrich last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies.

A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too was mixed,

Read More »

Breaking News

Breaking: Federal Judge Hands Down Mixed Opinion in Sanofi and Novo Nordisk’s 340B Contract Pharmacy Lawsuits

U.S. Chief District Judge Freda Wolfson ruled today that Sanofi and Novo Nordisk's 340B contract pharmacy policies violate the 340B statute. But she declined to decide whether the 340B statute permits covered entities to use multiple or unlimited contract pharmacies.

A federal district judge this afternoon upheld the federal government’s finding that drug manufacturers Sanofi and Novo Nordisk cannot unilaterally impose restrictions on offers of 340B pricing to covered entities and that their policies must cease.

U.S. Chief District Judge

Read More »

Feds Ask Judges to Follow Judge in Lilly Case and Validate HRSA’s Take on 340B Contract Pharmacy

DOJ has asked judges in five manufacturers' 340B contract pharmacy cases to follow to follow the lead of the judge in Lilly’s case and hold that these five companies’ contract pharmacy policies are illegal.

The federal government on Tuesday urged the judges in AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ separate 340B contract pharmacy lawsuits to follow the lead of the judge in Lilly’s case and hold that these five companies’ contract pharmacy

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live